High-throughput matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based deubiquitylating enzyme assay for drug discovery.
Virginia De CesareJennifer MoranRyan TraynorAxel KnebelMaria Stella RitortoMatthias TrostHilary McLauchlanC James HastiePaul DaviesPublished in: Nature protocols (2020)
Deubiquitylating enzymes (DUBs) play a vital role in the ubiquitin pathway by editing or removing ubiquitin from their substrate. As breakthroughs within the ubiquitin field continue to highlight the potential of deubiquitylating enzymes as drug targets, there is increasing demand for versatile high-throughput (HT) tools for the identification of potent and selective DUB modulators. Here we present the HT adaptation of the previously published MALDI-TOF-based DUB assay method. In a MALDI-TOF DUB assay, we quantitate the amount of mono-ubiquitin generated by the in vitro cleavage of ubiquitin chains by DUBs. The method has been specifically developed for use with nanoliter-dispensing robotics to meet drug discovery requirements for the screening of large and diverse compound libraries. Contrary to the most common DUB screening technologies currently available, the MALDI-TOF DUB assay combines the use of physiological substrates with the sensitivity and reliability of the mass spectrometry-based readout.
Keyphrases
- mass spectrometry
- high throughput
- drug discovery
- small molecule
- liquid chromatography
- capillary electrophoresis
- gas chromatography
- high performance liquid chromatography
- single cell
- high resolution
- crispr cas
- systematic review
- randomized controlled trial
- emergency department
- risk assessment
- human health
- solid phase extraction